A Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies
Latest Information Update: 01 Mar 2023
At a glance
- Drugs IBI 318 (Primary) ; Paclitaxel (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Innovent Biologics
- 23 Feb 2023 Status changed from recruiting to completed.
- 24 Dec 2020 Status changed from not yet recruiting to recruiting.
- 19 Dec 2020 New trial record